Doxycycline for Hereditary Hemorrhagic Telangiectasia
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study will investigate the effectiveness of oral doxycycline for the treatment of
recurrent nasal hemorrhage in Hereditary Hemorrhagic Telangiectasia (HHT) subjects. The
primary outcome for the trials will be the reduction of epistaxis severity (minutes of
bleeding per week). The biological outcomes of interest are the regression of vascular
malformations as well as tissue and circulation biomarkers of the relevant mechanistic
pathways. A Phase II, randomized double-blind placebo-controlled crossover trial.
Approximately 30 subjects with HHT, with moderate-severe recurrent epistaxis will participate
in the randomized double-blind placebo-controlled cross over trial. Subject will be treated
with a 6-month course of doxycycline 100mg twice daily or placebo twice daily.
Phase:
Phase 2
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto
Collaborators:
Barrow Neurological Institute Duke University Feinstein Institute for Medical Research Sunnybrook Health Sciences Centre University of Pittsburgh